CORT

Corcept Therapeutics Inc

Add to Watchlist

Advanced Chart

88.430

-1.89(-2.093%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

91.000

Open

91.000

VWAP

88.61

Vol

1.06M

Mkt Cap

9.32B

Low

85.610

Amount

94.02M

EV/EBITDA(TTM)

88.95

Total Shares

104.11M

9.17B

EV/OCF(TTM)

50.34

P/S(TTM)

14.92

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

223.78M

+22.59%

0.168

-59.15%

290.08M

+59.48%

0.445

+71.15%

246.43M

+56.74%

0.275

+61.76%

Estimates Revision

The market is revising Downward the revenue expectations for Corcept Therapeutics Incorporated (CORT) for FY2025, with the revenue forecasts being adjusted by -3.65% over the past three months. During the same period, the stock price has changed by 29.74%.

Revenue Estimates for FY2025

Revise Downward

-3.65%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-21.6%

In Past 3 Month

Stock Price

Go Up

+29.74%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 135.25 USD with a low forecast of 121.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 88.430

Low

121.00

Averages

135.25

High

145.00

Current: 88.430

Low

121.00

Averages

135.25

High

145.00

Canaccord

Buy

maintain

$137 -> $140

2025-09-10

Reason

Canaccord

Price Target

$137 -> $140

2025-09-10

maintain

Buy

Reason

Canaccord raised the firm's price target on Corcept Therapeutics to $140 from $137 and keeps a Buy rating on the shares. The firm met with management and updated its model to reflect the company's distribution fix and its oncology commercial infrastructure that they are building out to include the EU as well.

Canaccord

Edward Nash

Buy

downgrade

$142 -> $137

2025-08-01

Reason

Canaccord

Edward Nash

Price Target

$142 -> $137

2025-08-01

downgrade

Buy

Reason

Canaccord analyst Edward Nash lowered the firm's price target on Corcept Therapeutics to $137 from $142 and keeps a Buy rating on the shares. The firm noted they reported financial results and business highlights for 2Q25. Korlym product sales revenue was $194.4M for the quarter, slightly higher than the firm's estimate of $193M, representing an 18.7% Y/Y growth.

Piper Sandler

David Amsellem

Overweight

downgrade

$131 -> $121

2025-08-01

Reason

Piper Sandler

David Amsellem

Price Target

$131 -> $121

2025-08-01

downgrade

Overweight

Reason

Piper Sandler analyst David Amsellem lowered the firm's price target on Corcept Therapeutics to $121 from $131, owing mainly to slightly lower Korlym estimates and higher SG&A estimates, while keeping an Overweight rating on the shares. The firm notes Corcept reported Q2 diluted EPS of 29c on revenue of $194M, compared to Street estimates of 19c and $199M, respectively.

Piper Sandler

David Amsellem

Buy

Maintains

$128 → $131

2025-04-03

Reason

Piper Sandler

David Amsellem

Price Target

$128 → $131

2025-04-03

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Corcept Therapeutics to $128 from $78 and keeps an Overweight rating on the shares.

Canaccord Genuity

Edward Nash

Strong Buy

Maintains

$130 → $142

2025-04-01

Reason

Canaccord Genuity

Edward Nash

Price Target

$130 → $142

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Maintains

$115 → $150

2025-03-31

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$115 → $150

2025-03-31

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Corcept Therapeutics Inc (CORT.O) is 74.31, compared to its 5-year average forward P/E of 30.11. For a more detailed relative valuation and DCF analysis to assess Corcept Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Overvalued

5Y Average PE

30.11

Current PE

74.31

Overvalued PE

39.96

Undervalued PE

20.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

18.43

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

24.60

Undervalued EV/EBITDA

12.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.06

Current PS

0.00

Overvalued PS

7.40

Undervalued PS

4.72

Financials

Annual

Quarterly

FY2025Q2

YoY :

+18.70%

194.43M

Total Revenue

FY2025Q2

YoY :

-25.05%

26.68M

Operating Profit

FY2025Q2

YoY :

-0.96%

35.15M

Net Income after Tax

FY2025Q2

YoY :

-9.38%

0.29

EPS - Diluted

FY2025Q2

YoY :

+7.63%

43.88M

Free Cash Flow

FY2025Q2

YoY :

-0.23%

98.23

Gross Profit Margin - %

FY2025Q2

YoY :

+16.31%

25.17

FCF Margin - %

FY2025Q2

YoY :

-16.57%

18.08

Net Margin - %

FY2025Q2

YoY :

-12.32%

21.70

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

20.0M

USD

3-6

Months

20.1M

USD

6-9

Months

37.1M

USD

0-12

Months

2.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

20.0M

USD

3-6

Months

20.1M

USD

6-9

Months

37.1M

USD

0-12

Months

2.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CORT News & Events

Events Timeline

2025-09-10 (ET)

2025-09-10

08:08:18

Corcept Therapeutics reveals FDA has accepted relacorilant New Drug Application

2025-06-23 (ET)

2025-06-23

16:31:45

Corcept says Catalyst trial met primary endpoint

2025-06-05 (ET)

2025-06-05

06:04:44

Corcept Therapeutics' dazucorilant did not meet primary endpoint in ALS study

News

2.0

09-29Benzinga

4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance

5.0

09-28Yahoo Finance

Corcept Therapeutics Incorporated (NASDAQ:CORT) Sees 4.2% Weekly Gain, Pleasing Major Institutional Investors

6.5

09-25NASDAQ.COM

Analysts Predict 11% Growth Potential for FNX

People Also Watch

Sociedad Quimica y Minera de Chile SA

Lumen Technologies Inc

FAQ

What is Corcept Therapeutics Inc (CORT) stock price today?

The current price of CORT is 88.43 USD — it has decreased -2.09 % in the last trading day.

CORT

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CORT News & Events

Events Timeline

News

People Also Watch

FAQ

What is Corcept Therapeutics Inc (CORT) stock price today?

What is Corcept Therapeutics Inc (CORT)'s business?

What is the price predicton of CORT Stock?

What is Corcept Therapeutics Inc (CORT)'s revenue for the last quarter?

What is Corcept Therapeutics Inc (CORT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Corcept Therapeutics Inc (CORT)'s fundamentals?

How many employees does Corcept Therapeutics Inc (CORT). have?

What is Corcept Therapeutics Inc (CORT) market cap?